Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees.  The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.

Gilead Sciences, Inc. adalah perusahaan biofarmasi yang terlibat dalam penelitian, pengembangan, dan komersialisasi obat-obatan di bidang kebutuhan medis yang belum terpenuhi. Perusahaan ini berkantor pusat di Foster City, California dan saat ini mempekerjakan 17.000 karyawan penuh waktu. Perusahaan ini berfokus pada pengembangan obat-obatan untuk mencegah dan mengobati penyakit yang mengancam jiwa, termasuk HIV, hepatitis viral, COVID-19, kanker, dan peradangan. Perusahaan ini berkomitmen untuk menemukan, mengembangkan, dan menyediakan obat-obatan untuk memenuhi kebutuhan medis yang belum terpenuhi di bidang virologi, onkologi, dan area terapeutik lainnya. Portofolio produk yang dipasarkan mencakup Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, dan Letairis. Kandidat produknya mencakup Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, dan lainnya. Perusahaan juga mengembangkan program HB-400 dan program HB-500. Perusahaan mengembangkan terapi yang bertujuan untuk memberikan penyembuhan fungsional untuk virus hepatitis B dan virus imunodeficiency manusia-1. Perusahaan ini memiliki program kanker, yaitu TREX1. Perusahaan beroperasi di lebih dari 35 negara di seluruh dunia.

Gilead Sciences

Google

Apple

Microsoft

Amazon

Taiwan Semiconductor

Broadcom

Meta Platforms

Tesla

JPMorgan

Eli Lilly

Exxon Mobil

Oracle

Johnson & Johnson

ASML

MasterCard

Micron Technology

SPDR S&P500 ETF

Palantir

Costco

Bank of America

Chevron

General Electric

Procter & Gamble

Coca-Cola

AstraZeneca

Vanguard Total Stock Market ETF

Toyota

Caterpillar

Cisco

Merck

Lam Research

Novartis

Raytheon Technologies

Goldman Sachs

Wells Fargo

Applied Materials

American Express

Philip Morris

Royal Bank of Canada

Intel

Salesforce

T-Mobile

Shell

Invesco QQQ Trust

TotalEnergies

Blackstone

PepsiCo

Verizon

Charles Schwab

Disney

Amgen

Boeing

Abbott

Texas Instruments

Novo Nordisk

Intuitive Surgical

Southern Copper

Arista Networks

Pfizer

Shopify

Corning

Anheuser-Busch Inbev

Honeywell

Sony

QUALCOMM

Unilever

Deere

Lowe's

Danaher

ServiceNow

Banco Bilbao

Adobe

S&P Global

Palo Alto Networks

ConocoPhillips

Western Digital

Capital One

Chubb

CrowdStrike

Progressive

Seagate Technology

Sanofi

Medtronic

Vertex Pharmaceuticals

Bristol-Myers Squibb

Vanguard Dev Markets ETF

McKesson

Mercadolibre

Starbucks

Spotify

Comcast

Enbridge

Carvana

Agnico Eagle

General Dynamics

Vanguard Value ETF

Gilead Sciences Stock

About Gilead Sciences

Key Statistics

Insights

People Also Bought